What is GTBP's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for GTBP?

P/E (TTM) is n/a and 52-week range is $4.91 to $34.25 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s GTBP figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for GTBP?

The company profile lists revenue (TTM) near $65K, net income (TTM) near $-1.70B, EPS (TTM) near $-47.51 when available from the market-data feed. Figures are informational and may lag live markets.

Does GTBP show a dividend on Chartloom?

The overview lists dividend per share (TTM) near $0.41 when those figures are present. Dividend history is compiled from vendor data, not a distribution notice.

Where is GT Biopharma Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Francisco, California, US, 44.3M shares outstanding, ISIN US36254L3087 when available from company profile and filing metadata.

GT Biopharma Inc

$GTBP

Health Care · Biotechnology

IR Run Scenarios

$6.68

+12.08%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The company is headquartered in San Francisco, California and currently employs 1 full-time employees. The company went IPO on 2013-10-22. The firm is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The firm also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.

Employees

Website

www.gtbiopharma.com/

IPO

2013-10-22

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)